Merz, a German pharmaceutical company, is making great strides in the U.S. market for aesthetic medicine. On August 2nd, the company announced FDA approval for NT-201, a drug branded as XEOMIN. Along with the recently FDA approved Dysport and popular Botox®, it’s the 3rd botulinum toxin to enter the market.
A related company press release said, “XEOMIN does not require refrigeration prior to reconstitution,” a difference they say could “simplify product distribution and storage, and help ensure product integrity at the time of injection.”
In January, Merz announced the acquisition of California based Bioform Medical, maker of the popular Radiesse dermal filler. They say it’s a transaction that “advances Merz’s strategy of becoming a leading player in aesthetic medicine.”
Once the transaction is complete, Bioform will be renamed Merz Aesthetics and two new dermal fillers, Belotero® and Novabel®, will be introduced.
